Yüksel Ürün: Time, Doubling Rate, and Risk Matter More than One Number
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Ugo Giovanni Falagario et al. published in European Urology Oncology:
“Not all rising PSAs are equal.
A population study of 17,753 men redefines high-risk biochemical recurrence (HR-BCR) after prostate cancer treatment.
Half of men with a PSA rise don’t need treatment intensification. Time, doubling rate, and risk matter more than one number.
The EMBARK trial shows efficacy of early ENZA-based therapy, but in RP-only patients, we must be cautious:
- Excludes salvage RT setting
- Not designed to answer RT vs. systemic question
- Imaging used was conventional (CT/MRI/bone scan), not PSMA-PET.
- Real-world strategy might prioritize salvage RT ± short-term ADT, especially if PSMA-PET is negative!”
Title: Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment
Authors: Ugo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, Ahmad Abbadi, Alberto Martini, Alexander Valdman, Vincenza Conteduca, Giuseppe Carrieri, Giorgio Gandaglia, Alberto Briganti, Francesco Montorsi, Thorgerdur Palsdottir, Martin Eklund, Tobias Nordström, Henrik Grönberg, Markus Aly, Ash Tewari, Olof Akre, Anna Lantz, Peter Wiklund.
You can read the Full Article in European Urology Oncology.
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023